We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Could Provide Earlier Diagnosis of Liver Disease

By LabMedica International staff writers
Posted on 06 Sep 2012
A new "traffic light" test could be used in primary care to diagnose liver fibrosis and cirrhosis in high-risk populations.

Called the Southampton Traffic Light (STL) test, it combines several different tests and clinical markers, which are given a score that indicates the patient's likelihood of developing liver fibrosis and liver cirrhosis.

The STL algorithm combines two serum markers of fibrosis, collagen p3 n peptide (P3NP) and hyaluronic acid (HA), together with platelet count, and can be calculated in two ways: either with a complex exponential function derived from logistic regression analysis, or, alternatively, with a simple clinical rule for the individual test results:
HA >30 μg/L or P3NP >5.5 μg/L–score +1
HA >75 μg/L–score +2
Platelet count <150 × 109/L–score +1
Total score: 0 = green, 1 = amber, 2 or more = red

The “traffic light” aspect refers to grouping of the results of a combination of blood tests into “high risk,” “intermediate risk,” and “low risk” categories in terms of the patients' risk of developing serious liver disease. More...
The results are therefore actually numbers rather than traffic light-colored test tubes etc. The novel part is the grouping together of the individual tests such that their combined predictive value for the presence of liver disease is much greater than the tests when used individually.

The result is interpreted as follows: red means that the patient has liver scarring (fibrosis) and may even have cirrhosis, green means that there is no cirrhosis and the patient is highly unlikely to die from liver disease over the next five years. Amber means there is at least a 50:50 chance of scarring with a significant possibility of death within five years, and patients are advised to stop drinking to avoid further disease and death.

The test was given to more than 1,000 patients and their progress was followed and monitored, in some cases for several years, to assess the accuracy of the test in predicting whether they developed liver fibrosis or cirrhosis. It was accurate in severe liver disease but is not meant to be a substitute for clinical judgment or other liver function tests. However, it can provide family doctors with a means to assess the potential severity of liver fibrosis in high-risk patients such as heavy drinkers, those with type II diabetes, or obese individuals.

Devised by Dr. Nick Sheron and colleagues at University of Southampton (Southampton, United Kingdom) and Southampton General Hospital (Southampton, United Kingdom), details of the test appear in the September 2012 issue of the British Journal of General Practice (BJGP).

Prof. Sir Ian Gilmore, chair of the Alcohol Health Alliance commented, "One of the challenges of liver disease, which is rising dramatically in this country, is the silent nature of the condition until it is often too late to reverse the damage. However, minor changes in standard liver blood tests are so common that it is difficult for GPs to know when to refer for specialist advice. This large study from Dr .Sheron and colleagues in Southampton may prove really useful for guiding the right patients towards specialist care in a timely way."

Related Links:
University of Southampton
Southampton General Hospital




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.